EP Patent

EP4480491A1 — Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Assigned to Bayer Healthcare LLC · Expires 2024-12-25 · 1y expired

What this patent protects

The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, DR and DME characterized by high doses of aflibercept and lengthening intervals between doses.

USPTO Abstract

The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, DR and DME characterized by high doses of aflibercept and lengthening intervals between doses.

Drugs covered by this patent

Patent Metadata

Patent number
EP4480491A1
Jurisdiction
EP
Classification
—
Expires
2024-12-25
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Healthcare LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.